Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02390960 · ClinicalTrials.gov registry record · Phase 2
Phase 2a Topical Sildenafil Proof-of-Concept Study in Men With Mild to Moderate ED
A Phase 2 study, sponsored by Strategic Science & Technologies.
- Completed
- Registry status
- Phase 2
- Development phase
- 33
- Enrollment target
NCT02390960: Completed Phase 2 study, sponsored by Strategic Science & Technologies.
NCT02390960 is a Phase 2 study that has completed, run by Strategic Science & Technologies. The registered enrollment target is 33 participants, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (75% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02390960, a Phase 2 study, has completed, sponsored by Strategic Science & Technologies.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 33 participants
- Enrollment target
Study Summary
This is a Phase 2a, single-dose, double-blind, placebo-controlled, 2-way crossover study in men with ED. A single 2 gram dose of SST-6006 topical cream 5% w/w (formulated to deliver 100 mg of sildenafil) or a topical placebo cream will be applied to the penile shaft and glans. There are 4 study phases: the Initial Patient Screening Phase (Visit 1, an Off Site 4-Week Run-in Period and Visit 2), the Final Patient Screening Phase (Visit 3), the SST-6006/Placebo Double-Blind Dosing Phase (Visits 4-5), and the Follow-up Phase. Primary outcomes will be be evaluated at Weeks 7 and 8 of the study
Interventions
- DRUG Placebo Cream
- DRUG Sildenafil Cream
- DEVICE Penile Plethysmography (RigiScan)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 33 participants |
| Start Date | 2015-03 |
| Est. Completion | 2017-06 |
| Phase | Phase 2 |
What the finished NCT02390960 record still lists
NCT02390960 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 33 participants, a relatively small participant target, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (75% lower).
The record links to 0 conditions, and to 3 interventions - of which Placebo Cream is the first listed.
NCT02390960 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT02390960 about?
NCT02390960 is a clinical study titled "Phase 2a Topical Sildenafil Proof-of-Concept Study in Men With Mild to Moderate ED". This is a Phase 2a, single-dose, double-blind, placebo-controlled, 2-way crossover study in men with ED. A single 2 gram dose of SST-6006 topical cream 5% w/w (formulated to deliver 100 mg of sildenafil) or a topical placebo cream will be applied to the penile shaft and glans. There are 4 study phas...
What is the current status of trial NCT02390960?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 33 participants. The study started on 2015-03. Estimated completion is 2017-06.
What interventions are being tested in trial NCT02390960?
The interventions under investigation include: Placebo Cream (DRUG), Sildenafil Cream (DRUG), Penile Plethysmography (RigiScan) (DEVICE).
Who is sponsoring clinical trial NCT02390960?
This trial is sponsored by Strategic Science & Technologies, which has 8 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT02390960's enrollment target sits among peer trials
33 1553rd of 2000 higher than 438 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02861898 · 33 participants · Phase 1
Super-selective Intra-arterial Repeated Infusion of Cetuximab for the Treatment of Newly Diagnosed Glioblastoma
- NCT04871607 · 33 participants · Phase 2
Yttrium-90 Labeled Anti-CD25 Monoclonal Antibody Combined With BEAM Chemotherapy Conditioning for the Treatment of Primary Refractory or Relapsed Hodgkin Lymphoma
- NCT05071937 · 33 participants · Phase 2
ZEN003694 Combined With Talazoparib in Patients With Recurrent Ovarian Cancer
- NCT05168618 · 33 participants · Phase 2
Cabozantinib and Atezolizumab for the Treatment of Metastatic Castration-Resistant Prostate Cancer, The AtezoCab Trial
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia